- Home
- FTV vs ONC Comparison
FTV vs ONC Comparison
Compare FTV & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTV
- ONC
- Stock Information
- Founded
- FTV 2015
- ONC 2010
- Country
- FTV United States
- ONC Switzerland
- Employees
- FTV 18000
- ONC N/A
- Industry
- FTV Industrial Machinery/Components
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- FTV Industrials
- ONC Health Care
- Exchange
- FTV Nasdaq
- ONC Nasdaq
- Market Cap
- FTV 23.9B
- ONC 26.9B
- IPO Year
- FTV N/A
- ONC N/A
- Fundamental
- Price
- FTV $51.70
- ONC $243.64
- Analyst Decision
- FTV Buy
- ONC Strong Buy
- Analyst Count
- FTV 14
- ONC 9
- Target Price
- FTV $83.58
- ONC $325.56
- AVG Volume (30 Days)
- FTV 2.8M
- ONC 360.8K
- Earning Date
- FTV 07-23-2025
- ONC 08-06-2025
- Dividend Yield
- FTV 0.45%
- ONC N/A
- EPS Growth
- FTV N/A
- ONC N/A
- EPS
- FTV 2.28
- ONC N/A
- Revenue
- FTV $6,181,500,000.00
- ONC $4,175,868,000.00
- Revenue This Year
- FTV N/A
- ONC $869.15
- Revenue Next Year
- FTV $2.77
- ONC $19.07
- P/E Ratio
- FTV $31.38
- ONC N/A
- Revenue Growth
- FTV 0.85
- ONC 51.16
- 52 Week Low
- FTV $60.39
- ONC $141.31
- 52 Week High
- FTV $83.32
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- FTV 17.51
- ONC N/A
- Support Level
- FTV $69.90
- ONC N/A
- Resistance Level
- FTV $71.85
- ONC N/A
- Average True Range (ATR)
- FTV 1.30
- ONC 0.00
- MACD
- FTV -1.26
- ONC 0.00
- Stochastic Oscillator
- FTV 1.25
- ONC 0.00
About FTV Fortive Corporation
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.